Newswise — BOSTON – The field of precision cancer medicine has become so complex that even experienced oncologists can find it challenging to decipher the results of molecular tests of tumor tissue and navigate treatment options for patients. At Dana-Farber Cancer Institute, a multi-disciplinary team has been assisting gastrointestinal cancer physicians – reviewing test results and offering timely recommendations on treatment options.
A paper posted online today by JCO Precision Oncology reports that the program has largely fulfilled expectations, providing expert treatment guidance for more than 500 patients over the six-month evaluation period and identifying clinical trials appropriate for the majority of them. Overall, the team has reviewed test results for more than 2,700 patients to date. The findings suggest that the program can be a model for other cancer centers.
"Precision cancer medicine, which involves identifying key molecular changes within tumors and targeting them with the right drugs, has transformed the treatment of many malignancies," said the study's senior author, Marios Giannakis, MD, PhD, of Dana-Farber and the Broad Institute of MIT and Harvard. "To make the best decisions for patients, oncologists would ideally need an understanding of the intricacies of genomic testing and a working knowledge of cancer genetics – which can be difficult to apply in a busy clinic. Our program relieves oncologists of some of that burden by having a team of experts assist."
The program, dubbed GI TARGET (for Treatment Assistance Regarding Genomic Evaluation of Tumors), involved the creation of a multidisciplinary team of gastrointestinal oncologists, pathologists, genomic scientists, and research coordinators. The team functions as a molecular tumor board, reviewing tests for genomic abnormalities in patients' gastrointestinal tumors and identifying clinical trials of drugs (or off- and on-label therapies) that target those abnormalities.
The new paper reports results for 506 patients with gastrointestinal cancer treated at Dana-Farber Brigham Cancer Center between January and June 2019. Most of patient tumor samples were analyzed by OncoPanel, a test that can detect more than 450 genetic irregularities in tissue. The results were reviewed by the tumor board, which also used MatchMiner, a computational platform developed at Dana-Farber, to match patients to targeted therapy trials based on the genetic alterations in the patients' tumors. The board issued recommendations for treatment and other clinical actions, which were entered directly into patients' electronic medical record, where they could be reviewed by each patient's oncologist and other providers.
The board met weekly. The median time between the testing of tumor samples and the issuing of treatment recommendations was eight days.
"Our results show that precision medicine can be integrated into routine cancer care with a multidisciplinary tumor board, and that this program is both scalable and sustainable at a center like ours, which has a high volume of patients," Giannakis said.
This approach generated many actionable findings: the board was able to make clinical trial recommendations for 80% of the patients and recommended additional testing for 42%.
"The success of this program in gastrointestinal oncology at Dana-Farber suggests that similar programs could be implemented elsewhere, with investment of some resources and willingness to adjust workflows accordingly,” said Brian Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center at Dana-Farber.
The first author of the study is Rachel B. Keller, PhD, of Dana-Farber. Co-authors are Tali Mazor, PhD, Harshabad Singh, MBBS, Nilay Sethi, PhD, Adam Bass, MD, Ankur K. Nagaraja, MD, Lauren K. Brais, Emma Hill, Connor Hennessey, Margaret Cusick, Catherine Del Vecchio Fitz, PhD, Zachary Zwiesler, MS, Ethan Siegel, Andrea Ovalle, Pavel Trukhanov, MSc, Jason Hansel, Geoffrey I. Shapiro, MD, PhD, Thomas A. Abrams, MD, Leah H. Biller, MD, Jennifer A. Chan, MD, MPH, James M. Cleary, MD, PhD, Steven M. Corsello, MD, Andrea C. Enzinger, MD, Peter C. Enzinger, MD, Robert J. Mayer, MD, Nadine J. McCleary, MD, MPH, Jeffrey A. Meyerhardt, MD, MPH, Kimmie Ng, MD, MPH, Anuj K. Patel, MD, Kimberly J. Perez, MD, Osama E. Rahma, MD, Douglas A. Rubinson, MD, PhD, Jeffrey S. Wisch, MD, Matthew B. Yurgelun, MD, Michael J. Hassett, MD, MPH, Deborah Schrag, MD, MPH, Ethan Cerami, PhD, and Brian M. Wolpin, MD, MPH, of Dana-Farber; Andrew J. Aguirre, MD, PhD, of Dana-Farber and the Broad Institute; and Lynette Sholl, MD, Laura MacConaill, PhD, and Jonathan A. Nowak, MD, PhD, of Brigham and Women's Hospital.
GI TARGET was supported by philanthropic funding to the Gastrointestinal Cancer Center at Dana-Farber and by a grant from the Fund for Innovation in Cancer Informatics.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
# # #